DavidL.KreitzmanMD

Neurology • Commack, NY

Movement Disorder

Director, Parkinson’s Disease and Movement Disorders Center of Long Island

Join to view full profile

Dr. Kreitzman is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Connect with other colleagues in the same hospital or clinic
Search all U.S. specialist profiles and refer a patient
Read the latest clinical news and earn CME/CEU credits

See Dr. Kreitzman's full profile

Already have an account?

Office
Parkinson's Disease and Movement Disorders Center of Long Island (Private Practice)
283 Commack Road, Ste. 101
Commack, NY 11725
Phone+1 631-462-7774

Fax+1 631-462-7474
Is this information wrong?

Summary

Dr. Kreitzman is Director of the Parkinson’s Disease and Movement Disorders Center of Long Island in Commack, New York, and of the Parkinson’s Disease and Movement Disorders Clinic at St. Charles Hospital Specialty Care Center in Port Jefferson, New York.

After receiving his medical degree from St. George’s University School of Medicine in Grenada, Dr. Kreitzman completed a residency in neurology at University of Massachusetts Memorial Healthcare in Worchester, where he was Chief Resident in 2001, and a fellowship in Movement Disorders at Boston University School of Medicine in Massachusetts.

In 2003, he established the Parkinson's Disease and Movement Disorders Center of Long Island; serving as director. In 2011 Dr. Kreitzman established an additional Parkinson’s Disease center at St Charles Hospital Specialty Care Center and serves as Director.

A Diplomate of the American Board of Psychiatry and Neurology, Dr. Kreitzman is a member of the Movement Disorders Society, the Movement Disorders Section of the American Academy of Neurology, and the American Academy of Neurology. He has published numerous articles and abstracts in journals, has given scientific presentations at national and international meetings on Parkinson's disease and has completed over 50 clinical trials in Parkinson’s Disease.

Education & Training

Boston University Medical CenterFellowship, Movement Diisorders, 2002 - 2003
UMass Chan Medical SchoolResidency, Neurology, 1999 - 2002
Drexel University College of Medicine/Hahnemann University HospitalInternship, Internal Medicine, 1998 - 1999
St. George's University School of MedicineClass of 1998

Certifications & Licensure

NY State Medical License 2003 - 2024
CT State Medical License 1999 - 2003
PA State Medical License 1998 - 1999
American Board of Psychiatry and Neurology Neurology

Clinical Trials

Safety and Efficacy Study of CEP-1347 in the Treatment of Parkinson's Disease Start of enrollment: 2002 Mar 01
Terminated
Phase 2, Phase 3
Efficacy and Safety of Carbidopa/Levodopa/Entacapone in Patients With Parkinson's Disease Requiring Initiation of Levodopa Therapy Start of enrollment: 2004 Sep 01
Completed
Phase 3
Sarizotan in Participants With Parkinson's Disease Suffering From Treatment Associated Dyskinesia Start of enrollment: 2004 Sep 30
Completed
Phase 3
Sarizotan in Parkinson Patients With L-dopa-induced Dyskinesia Start of enrollment: 2002 Jul 01
Completed
Phase 2
Efficacy, Safety, and Tolerability of E2007 in Levodopa Treated Parkinson's Disease Patients With Motor Fluctuations Start of enrollment: 2006 Aug 01
Completed
Phase 3
Study to Evaluate Initiation of Stalevo in Early Wearing-off Start of enrollment: 2006 Sep 01
Completed
Phase 4
Safety/Efficacy of Tigan® to Control Nausea/Vomiting Experienced During Apokyn® Initiation and Treatment Start of enrollment: 2007 May 01
Completed
Phase 4
Impulse Control Disorders in Parkinson's Patients Treated With Pramipexole and Other Agents (DOMINION Study) Start of enrollment: 2006 Sep 01
Completed
A Study of Safety and Efficacy of Pimavanserin (ACP-103) in Patients With Parkinson's Disease Psychosis Start of enrollment: 2008 Mar 01
Completed
Phase 3
Azilect + Antidepressant Chart Review Start of enrollment: 2009 Jul 01
Completed
Study of NP002 in Subjects With Idiopathic Parkinson's Disease to Treat Dyskinesias Due to Levodopa Therapy Start of enrollment: 2009 Oct 01
Completed
Phase 1, Phase 2
Rasagiline as Add on to Dopamine Agonists in the Treatment of Parkinson's Disease Start of enrollment: 2009 Dec 01
Completed
Phase 4
An Open Label Extension Study of the Safety and Clinical Utility of IPX066 in Subjects With Parkinson's Disease Start of enrollment: 2010 Mar 01
Completed
Phase 3
A Study to Compare IPX066 and Carbidopa/Levodopa/Entacapone (CLE) Followed by an Open-Label Safety Study of IPX066 Start of enrollment: 2010 May 01
Completed
Phase 3
A Study of the Safety and Efficacy of Pimavanserin in Patients With Parkinson's Disease Psychosis Start of enrollment: 2010 Jul 01
Completed
Phase 3
A Two Part Study (306A/306B) to Assess Droxidopa in Treatment of NOH in Patients With Parkinson's Disease Start of enrollment: 2010 Jun 01
Completed
Phase 3
Placebo Controlled Study of Preladenant in Participants With Moderate to Severe Parkinson's Disease (P07037) Start of enrollment: 2010 Nov 19
Completed
Phase 3
ADX48621 for the Treatment of Levodopa Induced Dyskinesia in Patients With Parkinson's Disease Start of enrollment: 2011 Apr 01
Completed
Phase 2
Extended Release Amantadine Safety and Efficacy Study in Levodopa-Induced Dyskinesia (EASED Study) Start of enrollment: 2011 Jul 01
Completed
Phase 2, Phase 3
Carbidopa-Levodopa (CD-LD) ER Alone or in Combination With CD-LD IR to IPX066 Followed by IPX066 Extension Safety Study Start of enrollment: 2011 Aug 01
Completed
Phase 3
Parallel-Group Study to Assess the Effect of Rasagiline on Cognition in Patients With Parkinson's Disease Start of enrollment: 2012 Nov 01
Completed
Phase 4
Apokyn for Motor IMProvement of Morning AKinesia Trial (AM IMPAKT) Start of enrollment: 2012 Dec 01
Completed
Phase 4
ADS-5102 for the Treatment of Levodopa Induced Dyskinesia (EASE LID Study) Start of enrollment: 2014 May 01
Completed
Phase 3
Open-Label Phase 3 Study to Examine the Long-Term Safety, Tolerability and Efficacy of APL-130277 for the Acute Treatment of "OFF" Episodes in Patients With Parkinson's Disease Start of enrollment: 2015 Aug 31
Completed
Phase 3
Sustained Effect of Droxidopa in Symptomatic Neurogenic Orthostatic Hypotension Start of enrollment: 2016 Feb 11
Completed
Phase 4
A Study to Assess the Safety and Efficacy of the of the Gastric-retentive AP-CD/LD in Advanced Parkinson's Patients Start of enrollment: 2016 Mar 01
Unknown status
Phase 3
A Study of AP-CD/LD in Fluctuating Parkinson's Disease Patients Who Completed IN 11 004 Start of enrollment: 2016 Jul 01
Unknown status
Phase 3
Efficacy, Safety and Tolerability of PF-06649751 in Parkinson's Disease Patients With Motor Fluctuations Start of enrollment: 2016 Mar 03
Terminated
Phase 2
Safety and Tolerability of Tozadenant as Adjunctive Therapy in Levodopa-Treated Patients With Parkinson's Disease. Start of enrollment: 2017 Apr 10
Terminated
Phase 3
A Phase 3 Study With P2B001 in Subjects With Early Parkinson's Start of enrollment: 2018 Jan 19
Completed
Phase 3
Safety and Efficacy of Pimavanserin in Adults With Parkinson's Disease and Depression Start of enrollment: 2018 Mar 09
Completed
Phase 2
A Study to Evaluate the Safety and Efficacy of IPX203 in Parkinson's Disease Participants With Motor Fluctuations Start of enrollment: 2018 Nov 06
Completed
Phase 3
Open Label Extension (OLE) Study of the Safety and Clinical Utility of IPX203 in Parkinson's Disease (PD) Participants With Motor Fluctuations Start of enrollment: 2019 Apr 03
Completed
Phase 3
Utilization of Target Ranges to Treat Parkinson's Disease With the PKG Start of enrollment: 2019 Oct 15
Terminated
Not Applicable
Opicapone Treatment Initiation Open-Label Study Start of enrollment: 2021 Mar 01
Completed
Dipraglurant (ADX48621) for the Treatment of Patients With Parkinson's Disease Receiving Levodopa-based Therapy Start of enrollment: 2021 Aug 06
Recruiting
Phase 2, Phase 3
Join now to see all

Publications & Presentations

PubMed

9 citations
Efficacy results of pimavanserin from a multi-center, open-label extension study in Parkinson's disease psychosis patients.
Stuart Isaacson, Clive Ballard, David L Kreitzman, Bruce Coate, James C. Norton, Hubert H. Fernandez, Tihomir V. Ilić, Jean-Philippe Azulay, Joaquim J. Ferreira, Victo...> ;Parkinsonism & Related Disorders. 2021 Apr 28
A randomized study of rotigotine dose response on 'off' time in advanced Parkinson's disease.
Nicholas AP, Borgohain R, Chaná P, Surmann E, Thompson EL, Bauer L, Whitesides J, Elmer LW, SP921 Study Investigators> ;Journal of Parkinson's disease.
19 citations
Long-term evaluation of open-label pimavanserin safety and tolerability in Parkinson's disease psychosis.
Clive Ballard, David L Kreitzman, Stuart Isaacson, I-Yuan Liu, James C. Norton, George Demos, Hubert H. Fernandez, Tihomir V. Ilić, Jean-Philippe Azulay, Joaquim J. Fe...> ;Parkinsonism & Related Disorders. 2020 Jun 28
32 citations
Effect of using a wearable device on clinical decision-making and motor symptoms in patients with Parkinson's disease starting transdermal rotigotine patch: A pilot study
Stuart Isaacson, Babak Boroojerdi, Olga Waln, Martha McGraw, David L Kreitzman, Kevin J. Klos, Fredy J. Revilla, Dustin A. Heldman, Maureen Phillips, Dolors Terricabra...> ;Parkinsonism & Related Disorders. 2019 Jul 1
9 citations
Prevalence of Dyskinesia and OFF by 30-Minute Intervals Through the Day and Assessment of Daily Episodes of Dyskinesia and OFF: Novel Analyses of Diary Data from Gocov...
Robert A. Hauser, Daniel Kremens, Lawrence Elmer, David L. Kreitzman, Ryan R. Walsh, Reed Johnson, Robert Howard, Jack T. Nguyen, Rajiv Patni> ;Journal of Parkinson's Disease. 2019 Jan 1
19 citations
A randomized trial of a low-dose Rasagiline and Pramipexole combination (P2B001) in early Parkinson's disease.
C. Warren Olanow, Karl Kieburtz, Mika Leinonen, Lawrence Elmer, Nir Giladi, Robert A. Hauser, Olga S. Klepiskaya, David L. Kreitzman, Mark F. Lew, David S. Russell, Sh...> ;Movement Disorders. 2017 May 1
3 citations
Conversion to carbidopa and levodopa extended-release (IPX066) followed by its extended use in patients previously taking controlled-release carbidopa-levodopa for adv...
James W. Tetrud, Paul A. Nausieda, David L. Kreitzman, Grace S. Liang, Anette Nieves, Andrew P. Duker, Robert A. Hauser, Eric S. Farbman, Aaron Ellenbogen, Ann Hsu, Sh...> ;Journal of the Neurological Sciences. 2017 Feb 15
28 citations
Advances in levodopa therapy for Parkinson disease: Review of RYTARY (carbidopa and levodopa) clinical efficacy and safety.
Rohit Dhall, David Kreitzman> ;Neurology. 2016 Apr 5
Serotonin toxicity association with concomitant antidepressants and rasagiline treatment: retrospective study (STACCATO).
Panisset M, Chen JJ, Rhyee SH, Conner J, Mathena J, STACCATO study investigators> ;Pharmacotherapy. 2014-10-14
Immediate versus delayed switch from levodopa/carbidopa to levodopa/carbidopa/entacapone: effects on motor function and quality of life in patients with Parkinson's di...
Lew MF, Somogyi M, McCague K, Welsh M, Lce QoL Study Group> ;The International journal of neuroscience. 2011-08-16
Cerebral foreign body.
David Kreitzman, John Knorr> ;Archives of Neurology. 2003 Nov 1
Join now to see all

Press Mentions

David Kreitzman, MD: Restoring Parkinson’s Disease Patients’ Quality of Life at St. Charles HospitalOctober 23rd, 2020

Professional Memberships

American Academy of Neurology - AAN
Member
International Movement Disorders Society
Member

Hospital Affiliations

St. Charles HospitalPort Jefferson, New York